Advertisement


Christopher J. Sweeney, MBBS, on Localized Prostate Cancer: Metastasis-Free Survival as a Surrogate for Overall Survival

2016 ESMO Congress

Advertisement

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, discusses how this early clinical endpoint will accelerate the development of new therapies for localized intermediate and high-risk prostate cancer. (Abstract 717O)



Related Videos

Breast Cancer

Melanie Royce, MD, PhD, on Breast Cancer: Results From the BOLERO-4 Trial

Melanie Royce, MD, PhD, of the University of New Mexico, discusses phase II study findings on first-line everolimus plus letrozole in patients with ER+, HER2− advanced breast cancer. (Abstract 222O)

Genomics/Genetics
Solid Tumors

Janessa J. Laskin, MD, on Tumor Gene Expression and Advanced Cancers

Janessa J. Laskin, MD, of the British Columbia Cancer Agency, discusses the ways in which availability of tumor gene expression data facilitates clinical decision-making for patients with advanced cancers. (Abstract 1519O)

Skin Cancer

Omid Hamid, MD, on Melanoma: Results From the KEYNOTE-002 Study

Omid Hamid, MD, of The Angeles Clinic and Research Institute, discusses survival data from this clinical trial on pembrolizumab vs investigator-choice chemotherapy for ipilimumab-refractory melanoma. (Abstract 1107O) Follow him on Twitter: @omidhamidmd

Lymphoma

Teresa Calimeri, MD, PhD, on DLBCL: Findings on High-Dose Methotrexate

Teresa Calimeri, MD, PhD, of San Raffaele Hospital, discusses high-dose methotrexate as a CNS prophylaxis, shown to significantly improve outcome in patients with high-risk diffuse large B-cell lymphoma. (Abstract 908O)

Lung Cancer

Martin Reck, MD, PhD, on NSCLC: Results of KEYNOTE-024

Martin Reck, MD, PhD, of the LungenClinic, discusses study findings on pembrolizumab vs platinum-based chemotherapy as first-line therapy for advanced non-small cell lung cancer with a PD-L1 tumor proportion score ≥50%. (Abstract LBA8)

Advertisement

Advertisement




Advertisement